CorrealeJYsrraelitMCGaitanMI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain2009; 132: 1146–1160.
2.
ChangSHChungYDongC. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem2010; 285: 38751–38755.
3.
SmoldersJPeelenEThewissenM. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One201013; 5:e15235.
4.
AllenACKellySBasdeoSA. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler J2012; 18: 1797–800.
5.
McLeodJGHammondSRHallpikeJF. Epidemiology of multiple sclerosis in Australia. Med J Aust1994; 160: 117–22.
6.
TaylorBVPearsonJFClarkeG. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler J2010; 16: 1422–31.
7.
TaylorBVLucasRMDearK. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult Scler J2010; 16: 398–405.
8.
HutchinsonMZajicekJ. Clinically isolated syndrome: a protected zone for trials of new therapies?Mult Scler J2010; 16: 754–5.
MarcusJFShalevSMHarrisCAGoodinDSJosephsonSA. Severe hypercalcemia following vitamin D supplementation in a patient with multiple sclerosis: a note of caution. Arch Neurol2012; 69: 129–32.
11.
HanwellHEKimballSM. Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin D supplementation is a red herring. Arch Neurol2012; 69: 793; author reply 793–4.
